据天眼查，思埃然医疗成立于2022年7月，是一家集研发、生产、销售为一体的创新医疗器械企业，公 司核心团队有着丰富的行业经验，具备完整的研发-生产-商业化能力，专注于为眼科提供精准智能化微 创手术治疗方案，致力于打破国外企业在高端眼科手术器械领域的垄断，解决关键手术器械"卡脖子"问 题。 来源：猎云网 9月2日，眼科医疗器械创新企业思埃然医疗完成超亿元融资，由千骥资本、顺为资本联合领投，老股东 博行资本、弘晖基金持续加注，本轮融资资金将主要用于公司首款自主研发的超乳玻切一体机产品线的 深度研发推进，同时进一步丰富公司眼科手术设备产品矩阵，加速国产高端眼科器械的进口替代和公司 眼科产品的出海进程。 目前在研产品主要包括超乳玻切一体机及其配套耗材，数字化手术显微镜等高端眼科手术器械。 截至目前，公司已完成3轮亿元级融资。 ...

Core Insights - Honghui Fund's portfolio company, Siairan, has completed over 100 million yuan financing, led by Qianji Capital and Shunwei Capital, with existing investors including Boxin Capital and Honghui Fund increasing their stakes [1] - The funds will primarily be used for the in-depth research and development of the company's first self-developed phacoemulsification and vitrectomy integrated machine, as well as to expand the product matrix of ophthalmic surgical equipment [1] - Siairan Medical, established in July 2022, has a core team with extensive industry experience and complete capabilities in R&D, production, and commercialization [1] Company Overview - Siairan Medical focuses on providing precise and intelligent minimally invasive surgical solutions for ophthalmology, aiming to break the monopoly of foreign companies in the high-end ophthalmic surgical instrument sector [1] - The company is addressing critical issues related to key surgical instruments and is currently developing products including the phacoemulsification and vitrectomy integrated machine and digital surgical microscopes [1] - Siairan Medical is committed to offering innovative and high-quality products and services to ophthalmologists and patients, promoting the advancement of ophthalmic medical technology [1]